| Trial Name | Description |
| Keynote 564 Renal |
Dr. E. Winquist A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy |
| Checkmate 901 GU |
Dr. E. Winquist A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer |
| PCS 6 |
Dr. D'Souza Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI). |
| PCS IX |
Dr. Michael Lock The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial (PCS IX) |
| IND.232 GU |
Dr. E. Winquist A Phase II Study of Durvalumab (MEDI4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer |
| MISTER |
Dr. Eric Winquist Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer. |
| PR.19 |
Dr. David D'Souza "not yet open" A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. |
| CEC-CTC Renal |
Dr. A. Allan Prospective validation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) as prognostic biomarkers in clear cell renal cancer |
| CLEAR |
Dr. Eric Winquist A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carci |
| IND.223 |
Dr. Eric Winquist A Phase II Study of Palbociclib, A CDK 4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| REC.3 |
Dr. Kylea Potvin A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantanib [NSC#761968], Crizotinib [NSC#749005], Savolitinib [NSC#785348], and Sunitinib [NSC#736511])in Metastatic Papillary Renal Carcinoma (PAPMET). |
| Renal mTor |
Dr. M. Haeryfar Regulation of T cell responses by inhibitors of mammalian target of rapamycin (mTOR) |
| FASTR 2 GU |
Dr. B. Bauman Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer |
| OZM-053 GU |
Dr. Belal Ahmad A Phase II, Multi-Centre Study of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy |
| 5STAR PC |
Dr. Glenn Bauman "not yet open" 5 Fractions of Pelvic SABR with Intra prostatic SABR Boost: A Phase II Study (5STAR PC). |
| TRITON 2 |
Dr. Scott Ernst A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. |
| TRITON 3 |
Dr. Scott Ernst A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. |
| IND.234 |
Dr. Eric Winquist Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study. |
This information is updated by the Clinical Research Unit
